Skip to content
naulon

Not checkedNot checked for notices yet.

Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct

Söderlund Johan, Erhardt Sophie, Kast Richard E

Journal of Neuroinflammation · 2010

doi:10.1186/1742-2094-7-44 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Regulatory T cells, Tregs, are a subset of lymphocytes that have immunosuppressive attributes. They are elevated in blood of glioblastoma patients and within this tumor's tissue itself. Indoleamine 2,3-dioxygenase, IDO, converts tryptophan to kynurenine. IDO activity enhances Treg formation by pathways that are unknown. Experimentally, inhibition of IDO decreases Treg function and number in rodents. The common anti-viral agent acyclovir inhibits IDO. Acyclovir may thereby decrease Treg function in glioblastoma. If it can be confirmed that Treg counts are elevated in glioblastoma patients' tumor tissue, and if we can document acyclovir's lowering of tissue Treg counts by a small trial of acyclovir in pre-operative glioblastoma patients, a trial of acyclovir effect on survival should be done given the current poor prognosis of glioblastoma and the well-established safety and low side effect burden of acyclovir.</p>

Abstract licence: CC BY-NC-ND

References50

    40 more references, whose wording the paper’s licence keeps private.

    All 50 references

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.